No reports of adverse events related to the recall have been reported
TUESDAY, Nov. 3, 2020 (HealthDay News) — A cancer-causing compound in the drug metformin has resulted in the recall of two lots of the drug.
Kansas City-based Nostrum Laboratories Inc., said Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a notice from the U.S. Food and Drug Administration. No reports of adverse events related to the recall have been reported, the company said.
These tablets are tainted with higher-than-safe levels of the chemical nitrosamine, or NDMA. NDMA is a possible carcinogen, according to the U.S. Environmental Protection Agency.
The affected product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301, with the expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with “NM7.”
.jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
